Evolus, Inc.

Evolus, Inc. reported a significant improvement in its second-quarter 2026 financial results, with total net revenues increasing by 21.2% to $84.1 million and net loss narrowing to $8.1 million from $17.1 million in the prior year. For the first six months of 2026, net revenues grew 14.0% to $157.2 million, and net loss decreased to $18.7 million from $36.0 million. The company also launched four Evolysse® products in Europe and secured a new $30 million revolving credit facility.

Evolus, Inc. reported strong financial results for the second quarter ended June 30, 2026, with global net revenue reaching $84.1 million, a 21% increase over the prior year. The company achieved positive Adjusted EBITDA of $4.7 million for the third consecutive quarter, a significant improvement from a $7.9 million loss in Q2 2025. Based on these results, Evolus raised its full-year 2026 net revenue guidance to between $330 million and $337 million and increased its adjusted gross profit margin guidance. Additionally, Evolus expanded its global injectable portfolio through an exclusive U.S. partnership for Profhilo® and extended the Estyme® franchise into Canada, Australia, and New Zealand.

Evolus, Inc. announced an amendment to its existing license agreement with Symatese Aesthetics S.A.S., expanding its exclusive commercialization rights for Estyme® branded injectable hyaluronic acid gels to Canada, Australia, and New Zealand. This strategic move aims to establish a consistent multi-product commercial platform across Evolus' global business, complementing its existing neurotoxin franchise. Evolus Europe will make an upfront payment of €920,000 and up to €1.38 million upon regulatory approvals, with commercialization anticipated in 2028.

Evolus, Inc. reported a significant reduction in its net loss for the first quarter of 2026, narrowing to $10.67 million from $18.89 million in the prior year. Total net revenues increased by 6.7% to $73.14 million. The company also improved its loss from operations and reduced cash used in operating activities. Evolus secured a new $30 million revolving credit facility and terminated its At-the-Market Sales Agreement, having sold no shares. Milestone payments for Evolysse® products in Europe were triggered by October 2024 EU MDR approval, with payments due in October 2026 and December 2029.

Evolus, Inc. reported Q1 2026 financial results, achieving $73.1 million in global net revenue, a 7% increase year-over-year, and a second consecutive quarter of positive Adjusted EBITDA at $0.6 million. The company reaffirmed its full-year 2026 net revenue guidance of $327 million to $337 million and expects to achieve a low- to mid-single digit Adjusted EBITDA margin. Additionally, Evolus terminated its $50.0 million "at-the-market" sales agreement, under which no shares had been sold.

Evolus, Inc. announced its Annual Meeting of Stockholders will be held virtually on June 11, 2026, at 8:00 a.m. Pacific Time. Stockholders will consider proposals for the election of two Class II directors, Brady Stewart and Vikram Malik, who are nominated to serve until the 2029 annual meeting. Additionally, the agenda includes the ratification of Ernst & Young LLP as the independent registered public accounting firm for 2026 and an advisory vote on the compensation of the Company's named executive officers. The record date for stockholders entitled to vote is April 14, 2026.